|This is just a picture of the ballot
go to RFN to cast you ballot.
One of my favorite end-of-the-year traditions is Renal Fellow Network’s top nephrology stories of the year. Make sure you vote. The authors did a great job selecting 2013’s top stories of nephrology somehow they forgot the Omontys allergic reaction, voluntary recall and abandonment of peginesatide.
(I thought of one more but it escapes me, I’ll update this post when I remember it.)
Looking over the list, I think the story of the year is Tolvaptan’s failure to FDA gain approval for ADPKD. If Tolvaptan gains FDA approval in the next year or two following re-submission this story will quickly be forgotten. But if the future goes the other way, if Otsuka abandons tolvaptan for ADPKD and decides to remain in the limited ghetto of inpatient management of hyponatremia that would be a tragedy.
Part of what gets my blood boiling is the raging hypocrisy that the very same organization that approved:
- Zemplar (paricalcitol)
- Hecterol (doxercalciferol)
- Renagel (sevelamer)
- Renvela (sevelamer again)
- Fosrenal (lanthium carbonate)
- Sensipar (cinacalcet)
ADPKD slowed cyst growth and slowed the progression of kidney disease. Not just for one year but for three years! It joins ACEi/ARBs and insulin in the pantheon of drugs that can slow the progression of CKD (though bicarbonate and allopurionol are walking toward the door). Denying it was preposterous.